Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab
Shigeto Ueda, Toshiaki Saeki, Hideki Takeuchi, et al.
British Journal of Cancer (2016) Vol. 114, Iss. 11, pp. 1212-1218
Open Access | Times Cited: 98

Showing 1-25 of 98 citing articles:

Role of Immunotherapy in Triple-Negative Breast Cancer
Tanya E. Keenan, Sara M. Tolaney
Journal of the National Comprehensive Cancer Network (2020) Vol. 18, Iss. 4, pp. 479-489
Open Access | Times Cited: 445
Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges
John D. Martin, Giorgio Seano, Rakesh K. Jain
Annual Review of Physiology (2019) Vol. 81, Iss. 1, pp. 505-534
Open Access | Times Cited: 408
Angiogenesis as a hallmark of solid tumors - clinical perspectives
Jamal Majidpoor, Keywan Mortezaee
Cellular Oncology (2021) Vol. 44, Iss. 4, pp. 715-737
Closed Access | Times Cited: 191
Targeting the tumour vasculature: from vessel destruction to promotion
Sophie Guelfi, Kairbaan Hodivala‐Dilke, Gabriele Bergers
Nature reviews. Cancer (2024) Vol. 24, Iss. 10, pp. 655-675
Closed Access | Times Cited: 26
Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
Sara M. Tolaney, Romualdo Barroso‐Sousa, Tanya E. Keenan, et al.
JAMA Oncology (2020) Vol. 6, Iss. 10, pp. 1598-1598
Open Access | Times Cited: 120
Immunotherapy for early breast cancer: too soon, too superficial, or just right?
Maria Alice Franzoi, Emanuela Romano, Martine Piccart
Annals of Oncology (2020) Vol. 32, Iss. 3, pp. 323-336
Open Access | Times Cited: 103
Checkpoint inhibitor therapy for metastatic triple-negative breast cancer
Arielle L. Heeke, Antoinette R. Tan
Cancer and Metastasis Reviews (2021) Vol. 40, Iss. 2, pp. 537-547
Open Access | Times Cited: 95
Microtubule-Targeting Drugs: More than Antimitotics
Roma Kaul, April L. Risinger, Susan L. Mooberry
Journal of Natural Products (2019) Vol. 82, Iss. 3, pp. 680-685
Closed Access | Times Cited: 84
Vascular Normalization: A New Window Opened for Cancer Therapies
Ting Yang, Hongqi Xiao, Xiaoxia Liu, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 73
Selective tubulin-binding drugs induce pericyte phenotype switching and anti-cancer immunity
Bo He, Kira H Wood, Zhijie Li, et al.
EMBO Molecular Medicine (2025)
Open Access | Times Cited: 1
MORAb-202, an Antibody–Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity
Xin Cheng, Jing Li, Keigo Tanaka, et al.
Molecular Cancer Therapeutics (2018) Vol. 17, Iss. 12, pp. 2665-2675
Open Access | Times Cited: 74
Eribulin Promotes Antitumor Immune Responses in Patients with Locally Advanced or Metastatic Breast Cancer
Wataru Goto, Shinichiro Kashiwagi, Yuka Asano, et al.
Anticancer Research (2018) Vol. 38, Iss. 5
Open Access | Times Cited: 72
Multiple modes of action of eribulin mesylate: Emerging data and clinical implications
Javier Cortés, Patrick Schöffski, Bruce A. Littlefield
Cancer Treatment Reviews (2018) Vol. 70, pp. 190-198
Open Access | Times Cited: 68
Antitumor effects of eribulin depend on modulation of the tumor microenvironment by vascular remodeling in mouse models
Ken Ito, Shusei Hamamichi, Takanori Abe, et al.
Cancer Science (2017) Vol. 108, Iss. 11, pp. 2273-2280
Open Access | Times Cited: 63
High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin—but not with treatment of physician’s choice—in the EMBRACE study
Yasuo Miyoshi, Yuta Yoshimura, Kenichi Saito, et al.
Breast Cancer (2020) Vol. 27, Iss. 4, pp. 706-715
Open Access | Times Cited: 60
Significant Association Between Low Baseline Neutrophil-to-Lymphocyte Ratio and Improved Progression-free Survival of Patients With Locally Advanced or Metastatic Breast Cancer Treated With Eribulin But Not With Nab-Paclitaxel
Yoshimasa Miyagawa, Kazuhiro Araki, Ayako Bun, et al.
Clinical Breast Cancer (2018) Vol. 18, Iss. 5, pp. 400-409
Open Access | Times Cited: 47
Antibody‐drug conjugate MORAb‐202 exhibits long‐lasting antitumor efficacy in TNBC PDx models
Keiji Furuuchi, Katherine A. Rybinski, James Fulmer, et al.
Cancer Science (2021) Vol. 112, Iss. 6, pp. 2467-2480
Open Access | Times Cited: 29
Efficacy of Eribulin in Soft Tissue Sarcomas
Edward Phillips, Robin L. Jones, Paul H. Huang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 20
Imaging of breast cancer using reflectance diffuse optical tomography (RDOT)
Nobuko Yoshizawa, Yuko Asano, Kenji Yoshimoto, et al.
Optical Review (2025)
Closed Access
Quantitative proteomics analysis of triple-negative breast cancers
Natasha C. Mariano, Jonathan D. Marotti, Youdinghuan Chen, et al.
npj Precision Oncology (2025) Vol. 9, Iss. 1
Open Access
Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer
Natsuko Satomi-Tsushita, Akihiko Shimomura, Juntaro Matsuzaki, et al.
PLoS ONE (2019) Vol. 14, Iss. 9, pp. e0222024-e0222024
Open Access | Times Cited: 33
A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience
Junichiro Watanabe, Mitsue Saito, Yoshiya Horimoto, et al.
Breast Cancer Research and Treatment (2020) Vol. 181, Iss. 1, pp. 211-220
Open Access | Times Cited: 32
Circulating Cytokines in Metastatic Breast Cancer Patients Select Different Prognostic Groups and Patients Who Might Benefit from Treatment beyond Progression
Matteo Paccagnella, Andrea Abbona, Andrea Michelotti, et al.
Vaccines (2022) Vol. 10, Iss. 1, pp. 78-78
Open Access | Times Cited: 18
Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody
Yuki Niwa, Keito Adachi, Kimiyo Tabata, et al.
Molecular Cancer Therapeutics (2023) Vol. 22, Iss. 4, pp. 499-510
Open Access | Times Cited: 10
Novel Anti-FOLR1 Antibody–Drug Conjugate MORAb-202 in Breast Cancer and Non-Small Cell Lung Cancer Cells
Yuki Matsunaga, Toshimitsu Yamaoka, Motoi Ohba, et al.
Antibodies (2021) Vol. 10, Iss. 1, pp. 6-6
Open Access | Times Cited: 20
Page 1 - Next Page

Scroll to top